sec filing
EN
NASDAQ · ENGN
enGene Holdings Inc.
Healthcare · Biotechnology
$1.89
Up+$0.02 (+1.07%)
Updated Sep 16, 2026, 10:53 AM
SID Score
4.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 455.64M
- P/E ratio
- -10.55
- Dividend yield
- 0.00%
- 52-week range
- $1.40 – $9.00
- Volume
- 618.75K
- Avg. volume
- 1.26M
Price performance
ENGN price history
1M range · 20 trading sessions · Daily adjusted prices
ENGN closed at $1.89 after 20 trading sessions, up 9.88% for the selected period.
- Last close
- $1.89
- Period change
- +9.88%
- Period low
- $1.72
- Period high
- $1.95
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $1.87 | $1.90 | $1.845 | $1.89 | 618.75K |
| Sep 14, 2026 | $1.80 | $1.88 | $1.80 | $1.87 | 460.52K |
| Sep 11, 2026 | $1.80 | $1.83 | $1.79 | $1.80 | 651.01K |
| Sep 10, 2026 | $1.85 | $1.85 | $1.76 | $1.77 | 565.33K |
| Sep 9, 2026 | $1.89 | $1.92 | $1.84 | $1.85 | 486.38K |
| Sep 8, 2026 | $1.82 | $1.94 | $1.78 | $1.92 | 1.51M |
| Sep 4, 2026 | $1.82 | $1.835 | $1.78 | $1.82 | 412.68K |
| Sep 3, 2026 | $1.90 | $1.91 | $1.80 | $1.83 | 634.65K |
| Sep 2, 2026 | $1.84 | $1.9188 | $1.835 | $1.89 | 1.06M |
| Sep 1, 2026 | $1.84 | $1.8699 | $1.80 | $1.855 | 657.38K |
| Aug 31, 2026 | $1.83 | $1.855 | $1.81 | $1.84 | 291.28K |
| Aug 28, 2026 | $1.91 | $1.91 | $1.81 | $1.825 | 447.14K |
| Aug 27, 2026 | $1.94 | $1.94 | $1.91 | $1.91 | 252.12K |
| Aug 26, 2026 | $1.87 | $1.95 | $1.87 | $1.95 | 1.83M |
| Aug 25, 2026 | $1.82 | $1.886 | $1.815 | $1.87 | 1.01M |
| Aug 24, 2026 | $1.79 | $1.83 | $1.75 | $1.81 | 642.5K |
| Aug 21, 2026 | $1.795 | $1.805 | $1.77 | $1.78 | 242.73K |
| Aug 20, 2026 | $1.84 | $1.85 | $1.755 | $1.77 | 368.44K |
| Aug 19, 2026 | $1.73 | $1.895 | $1.73 | $1.85 | 1.26M |
| Aug 18, 2026 | $1.70 | $1.74 | $1.69 | $1.72 | 690.94K |
Latest ENGN news
The latest Smart Investors Daily articles mentioning ENGN.
Stock researchCompany · Overview
ENGN research
Overview
Company profile and research snapshot.
Company profile
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $22.67
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | Citizens | Market Perform | — |
| Sep 8, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 18, 2026 | Morgan Stanley | Underweight | — |
| Jun 16, 2026 | HC Wainwright & Co. | Buy | — |
| May 14, 2026 | UBS | Neutral | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.